VickJW
2021-11-23
Like and comment please
Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":875524880,"tweetId":"875524880","gmtCreate":1637672252853,"gmtModify":1637672252978,"author":{"id":3578439260866475,"idStr":"3578439260866475","authorId":3578439260866475,"authorIdStr":"3578439260866475","name":"VickJW","avatar":"https://static.tigerbbs.com/dc8189137ac06a254539a020b5b368b2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment please</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment please</p></body></html>","text":"Like and comment please","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875524880","repostId":1197163617,"repostType":4,"repost":{"id":"1197163617","kind":"news","pubTimestamp":1637671759,"share":"https://www.laohu8.com/m/news/1197163617?lang=&edition=full","pubTime":"2021-11-23 20:49","market":"us","language":"en","title":"Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1197163617","media":"Benzinga","summary":"The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable ","content":"<ul>\n <li>The FDA has approved <b>Aadi Bioscience Inc's</b> Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa).</li>\n</ul>\n<ul>\n <li>The approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa.</li>\n <li>PEComa is a family of rare tumors that form in the soft tissues of the stomach, intestines, lungs, female reproductive organs, and genitourinary organs.</li>\n <li>In Phase 2 registrational AMPECT trial, the overall response rate was 39% (12/31), with two patients achieving a Complete Response after prolonged follow-up.</li>\n <li>The median duration of response has not been reached, with a median follow-up of 36 months.</li>\n <li>Among responders, 92% had a response lasting greater than or equal to 6 months; 67% had a response lasting up to 12 months, and 58% had a response lasting up to 2 years.</li>\n <li><b>Price Action:</b> AADI shares are up 42.6% at $36.39 during the premarket session on the last check Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 20:49 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa).\n\n\nThe approval marks ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AADI":"Aadi Biosciences, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197163617","content_text":"The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa).\n\n\nThe approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa.\nPEComa is a family of rare tumors that form in the soft tissues of the stomach, intestines, lungs, female reproductive organs, and genitourinary organs.\nIn Phase 2 registrational AMPECT trial, the overall response rate was 39% (12/31), with two patients achieving a Complete Response after prolonged follow-up.\nThe median duration of response has not been reached, with a median follow-up of 36 months.\nAmong responders, 92% had a response lasting greater than or equal to 6 months; 67% had a response lasting up to 12 months, and 58% had a response lasting up to 2 years.\nPrice Action: AADI shares are up 42.6% at $36.39 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":372,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/875524880"}
精彩评论